嚢胞性線維症市場

The secondary research process involved comprehensive analysis of clinical registries, regulatory databases, peer-reviewed respiratory and genetic medicine journals, and authoritative health organizations specific to cystic fibrosis care. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Cystic Fibrosis Foundation (CFF) Patient Registry, European Cystic Fibrosis Society (ECFS) Patient Registry, UK Cystic Fibrosis Registry, National Institutes of Health (NIH) / National Heart, Lung, and Blood Institute (NHLBI), Centers for Disease Control and Prevention (CDC) Newborn Screening Data, World Health Organization (WHO) Genetic Disorders Observatory, ClinicalTrials.gov, PubMed/NCBI (Journal of Cystic Fibrosis, Pediatric Pulmonology, American Journal of Respiratory and Critical Care Medicine), Cystic Fibrosis Trust (UK), Cystic Fibrosis Canada, Therapeutic Goods Administration (TGA) Australia, and national CF registry reports from France (Registre de la Mucoviscidose), Germany (Muko-Register), and Australia (ACFDR). These sources were used to collect epidemiological statistics, patient registry data, regulatory approval status for CFTR modulators and gene therapies, clinical safety and efficacy studies, newborn screening trends, and competitive landscape analysis across CFTR modulators, mucolytics (dornase alfa, hypertonic saline), bronchodilators, antibiotics (tobramycin, aztreonam), and pancreatic enzyme replacement therapies.

Supply-side and demand-side stakeholders were interviewed during the primary research process to acquire qualitative and quantitative insights that were unique to the cystic fibrosis therapeutic landscape. Senior executives from CROs that manage CF clinical trials, diagnostic companies (genetic testing providers), and medical device manufacturers (nebulizers, vibrating mesh inhalers) were among the supply-side sources. These sources included CEOs, CFOs, Global Heads of R&D, Chief Medical Officers, Heads of Rare Disease Commercial Strategy, Market Access Directors, and Gene Therapy Portfolio Leads from pharmaceutical manufacturers that specialize in CFTR modulators and cystic fibrosis therapeutics. The demand-side sources included adult and pediatric pulmonologists who specialized in cystic fibrosis, directors of accredited CF Care Centers, clinical coordinators from academic medical centers, respiratory therapists, specialty pharmacists (particularly those who specialize in rare disease therapeutics), patient advocacy group representatives (Cystic Fibrosis Foundation chapters), procurement leads from integrated hospital networks, and payer representatives who manage orphan drug reimbursement and specialty tier pharmacy benefits.

Primary research validated market segmentation by drug class and route of administration, confirmed gene therapy and next-generation CFTR modulator pipeline timelines, and gathered insights on clinical adoption patterns of triple-combination therapies, pricing and access barriers for high-cost CFTR modulators, real-world patient adherence data, newborn screening expansion impacts on diagnosis rates, and reimbursement dynamics across private and public payer systems.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (38%), Others (30%)

By Region: North America (40%), Europe (25%), Asia-Pacific (22%), Rest of World (13%)

By Stakeholder Category: Biopharma Manufacturers (45%), Healthcare Providers/CF Center Directors (30%), Payers & Market Access (15%), Patient Advocacy & CROs (10%)

Global market valuation was derived through revenue mapping, patient population epidemiology analysis, and treatment volume modeling. The methodology included:

Identification of 35+ key manufacturers and emerging biotechs across North America, Europe, and Asia-Pacific specializing in CFTR modulators, gene therapy, and supportive care medications

Product mapping across CFTR modulators (potentiators, correctors, stabilizers), mucolytics, bronchodilators, antibiotics (inhaled and systemic), and pancreatic enzyme supplements, with specific analysis of Vertex Pharmaceuticals' portfolio dominance (Trikafta/Kaftrio, Orkambi, Symdeko, Kalydeco) and emerging competitors

Analysis of reported and modeled annual revenues specific to cystic fibrosis therapeutic portfolios, including gene therapy candidates in Phase I/II

Coverage of manufacturers and gene therapy developers representing 75-80% of global cystic fibrosis market share in 2024

Epidemiological bottom-up modeling utilizing country-specific patient registry data (US CFF Registry, ECFS Registry, UK CF Registry) to determine treated versus untreated populations, segmented by age (pediatric vs. adult), mutation class (F508del homozygous, heterozygous, minimal function), and disease severity

Pricing analysis across oral CFTR modulators, inhaled antibiotics, and pancreatic enzyme supplements by region, incorporating value-based pricing and orphan drug premium structures

Extrapolation using bottom-up (country-specific CF prevalence × diagnosis rate × treatment penetration × annual drug cost/ASP) and top-down (manufacturer revenue validation, pharmaceutical sales data) approaches to derive segment-specific valuations for CFTR modulators versus supportive care medications